Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresect...
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
About this item
Full title
Author / Creator
Su, Dan , Wu, Bin and Shi, Lizheng
Publisher
United States: American Medical Association
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Medical Association
Subjects
More information
Scope and Contents
Contents
Treatment with atezolizumab plus bevacizumab may prolong overall survival among patients with unresectable hepatocellular carcinoma. However, to our knowledge, the cost-effectiveness of using this high-priced therapy for this indication is currently unknown.
To evaluate the cost-effectiveness of atezolizumab plus bevacizumab to treat unresectabl...
Alternative Titles
Full title
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7905498
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7905498
Other Identifiers
ISSN
2574-3805
E-ISSN
2574-3805
DOI
10.1001/jamanetworkopen.2021.0037
